aTyr Pharma, Inc. (LIFE)
- Previous Close
1.5900 - Open
1.6000 - Bid 1.6100 x 400
- Ask 1.6400 x 400
- Day's Range
1.5800 - 1.6400 - 52 Week Range
1.0800 - 2.7000 - Volume
262,976 - Avg. Volume
558,616 - Market Cap (intraday)
110.064M - Beta (5Y Monthly) 1.23
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9400 - Earnings Date May 7, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
22.60
aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
www.atyrpharma.comRecent News: LIFE
Performance Overview: LIFE
Trailing total returns as of 4/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LIFE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LIFE
Valuation Measures
Market Cap
110.40M
Enterprise Value
27.33M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
246.77
Price/Book (mrq)
1.22
Enterprise Value/Revenue
77.43
Enterprise Value/EBITDA
-0.52
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-31.72%
Return on Equity (ttm)
-62.31%
Revenue (ttm)
353k
Net Income Avi to Common (ttm)
-50.39M
Diluted EPS (ttm)
-0.9400
Balance Sheet and Cash Flow
Total Cash (mrq)
98.17M
Total Debt/Equity (mrq)
16.69%
Levered Free Cash Flow (ttm)
-21.18M
Research Analysis: LIFE
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell